Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216224 · ClinicalTrials.gov registry record · Phase 2
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT05216224 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 95 participants.
The verdict
NCT05216224, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Interventions
- DRUG Placebo oral tablet
- DRUG ATI-450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2023-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05216224
The ClinicalTrials.gov registry entry for NCT05216224 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT05216224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05216224 about?
NCT05216224 is a clinical study titled "ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)". This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
What is the current status of trial NCT05216224?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2021-12-29. Estimated completion is 2023-01-24.
What interventions are being tested in trial NCT05216224?
The interventions under investigation include: Placebo oral tablet (DRUG), ATI-450 (DRUG).
Who is sponsoring clinical trial NCT05216224?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.